Plural Ring Nitrogens In The Tricyclo Ring System Patents (Class 546/81)
  • Patent number: 10197557
    Abstract: The present invention provides small molecules for endothelial cell activation and compositions thereof and methods of making and using the same.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: February 5, 2019
    Assignee: The Regents of the University of California
    Inventors: Daniel Cruz, Ohyun Kwon
  • Patent number: 10174044
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Susheel Jethanand Nara, Carolyn Diane Dzierba, John E. Macor, Joanne J. Bronson, Rajamani Ramkumar, Tarun Kumar Maishal, Maheswaran Sivasamban Karatholuvhu, Soodamani Thangavel, Kamalraj Thiyagarajan
  • Patent number: 10112941
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: October 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Francis Y. Lee, John S. Tokarski
  • Patent number: 10040797
    Abstract: The invention provides compounds of Formula 1: or a stereoisomer, pharmaceutically acceptable salt, or mixture thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: August 7, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 10040796
    Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: August 7, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 10011599
    Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: July 3, 2018
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
  • Patent number: 9938268
    Abstract: Disclosed are C-ring modified tricyclic benzonaphthiridinone compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Yufang Xiao, Bayard R. Huck, Amanda E. Sutton, Thomas E. Richardson, Srinivasa R. Karra
  • Patent number: 9902734
    Abstract: The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula I. Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine receptor agonists.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: February 27, 2018
    Assignees: Indiana State University, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Richard W. Fitch, Thomas F. Spande, H. Martin Garraffo, Herman J. C. Yeh, John W. Daly
  • Patent number: 9850241
    Abstract: The present invention relates to azaindolle acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: December 26, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • Patent number: 9751879
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, Jr., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Patent number: 9692003
    Abstract: The present invention discloses a phenanthroline derivative is represented by the following formula(I), the organic EL device employing the phenanthroline derivative as hole blocking electron transport material, electron transport material can display good performance like as lower driving voltage and power consumption, increasing efficiency and half-life time. wherein Ar, m, n, p and R1 to R4 are the same definition as described in the present invention.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: June 27, 2017
    Inventor: Feng-Wen Yen
  • Patent number: 9657019
    Abstract: A 1,9-diazaphenalene derivative is represented by where R, R1, R2, R3, Y1, and Y2 are as defined in the specification and claims. The 1,9-diazaphenalene derivative may emit fluorescence after being excited, and is thus suitable for use as a fluorescent material for an organic light emitting diode. A method for preparing the 1,9-diazaphenalene derivative is also disclosed.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 23, 2017
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Chien-Hong Cheng, Jayachandran Jayakumar, Min-Hsien Chen
  • Patent number: 9458156
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: October 4, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Francis Y. Lee, John S. Tokarski
  • Patent number: 9227969
    Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: January 5, 2016
    Assignee: NOVARTIS AG
    Inventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
  • Patent number: 9040172
    Abstract: The present invention describes novel indenofluorene derivatives which can preferably be employed as matrix materials for phosphorescent dopants or as electron-transport materials, in particular for use in the emission and/or charge-transport layer of electroluminescent devices. The invention furthermore relates to polymers which comprise these compounds as structural units and to a process for the preparation of the compounds according to the invention and to electronic devices which comprise same.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: May 26, 2015
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Teresa Mujica-Fernaud, Arne Buesing, Holger Heil
  • Patent number: 9040175
    Abstract: The present invention relates to an electronic device comprising at least one organic semiconducting material according to the following formula (I): wherein R1-4 are independently selected from H, halogen, CN, substituted or unsubstituted C1-C20-alkyl or heteroalkyl, C6-C20-aryl or C5-C20-heteroaryl, C1-C20-alkoxy or C6-C20-aryloxy, Ar is selected from substituted or unsubstituted C6-C20-aryl or C5-C20-heteroaryl, and R5 is selected from substituted or unsubstituted C6-C20-aryl or C5-C20-heteroaryl, H, F or formula (II).
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: May 26, 2015
    Assignee: NOVALED AG
    Inventors: Omrane Fadhel, Ramona Pretsch
  • Patent number: 9034485
    Abstract: The present invention relates to compounds of the formula (1) and to the use thereof in organic electronic devices, and to organic electronic devices which comprise compounds of the formula (1), preferably as hole-transport materials and/or as emitting materials.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: May 19, 2015
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Holger Heil, Philipp Stoessel, Amir Hossain Parham, Rocco Fortte, Jonas Valentin Kroeber
  • Patent number: 9029387
    Abstract: The present invention relates to benzonaphthyridinamines of the formula (I) as autotaxin inhibitors and to the use thereof in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in which the inhibition, regulation and/or modulation of phosphodiesterase or lysophospholipase autotaxin plays a role, in particular of various types of cancer and autoimmune and inflammatory diseases.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: May 12, 2015
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Melanie Schultz, Kai Schiemann
  • Patent number: 9017829
    Abstract: The present invention relates to a material for an organic electroluminescent device, including a phenanthrocarbazole-based compound having a specific structure, and an organic electroluminescent device including the same. More specifically, the phenanthrocarbazole-based compound is applied as a material for a phosphorescent and fluorescent organic electroluminescent device, thereby providing an organic light emitting device with improved light emitting efficiency, luminance, thermal stability, driving voltage, lifetime and the like.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: April 28, 2015
    Assignee: Doosan Corporation
    Inventors: Jin-Seok Hong, Eun Jung Lee, Shin Han Kim, Kyoung-Soo Kim
  • Patent number: 8999526
    Abstract: An organic photoelectric device may include an anode and a cathode configured to face each other, and an active layer between the anode and cathode, wherein the active layer includes a quinacridone derivative and a thiophene derivative having a cyanovinyl group.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: April 7, 2015
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Kwang Hee Lee, Kyu Sik Kim, Kyung Bae Park, Dong-Seok Leem, Seon Jeong Lim
  • Patent number: 8986852
    Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: March 24, 2015
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Arne Buesing, Holger Heil
  • Patent number: 8986857
    Abstract: Provided is a novel compound which can be used for a transport layer or as a host material or a light-emitting material in a light-emitting element and with which a high-performance light-emitting element can be manufactured. A dibenzo[c,g]carbazole compound in which an aryl group having 14 to 30 carbon atoms and including at least anthracene is bonded to nitrogen of a dibenzo[c,g]carbazole derivative is synthesized. By use of the dibenzo[c,g]carbazole compound, a light-emitting element having very good characteristics can be obtained.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: March 24, 2015
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hiroki Suzuki, Satoshi Seo, Sachiko Kawakami, Tsunenori Suzuki
  • Patent number: 8962157
    Abstract: Compounds of formula I may be used in optoelectronic devices wherein R1, R2 and R4 are, independently at each occurrence, H, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; R3 is H or a is, independently at each occurrence, 1 or 2; b is, independently at each occurrence, an integer ranging from 0-3; c is, independently at each occurrence, an integer ranging from 0-4; Ar is independently at each occurrence, H, or heteroaryl; and at least two of Ar are heteroaryl.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: February 24, 2015
    Assignee: General Electric Company
    Inventors: Qing Ye, Jie Liu, Kelly Scott Chichak, Yangang Liang
  • Patent number: 8951647
    Abstract: The present invention relates to organic electroluminescent devices which comprise fluorene derivatives and spirobifluorene derivatives as matrix material for phosphorescent emitters.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: February 10, 2015
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Joachim Kaiser, Anja Gerhard, Jonas Valentin Kroeber
  • Patent number: 8932732
    Abstract: The present invention relates to organic electroluminescent devices, in particular blue-emitting devices, in which compounds of the formulae (1) to (4) are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: January 13, 2015
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Philipp Stoessel, Holger Heil
  • Patent number: 8932734
    Abstract: Compounds comprising a 3,9-linked oligocarbazole moiety and a dibenzothiophene, dibenzofuran, dibenzoselenophene, aza-dibenzothiophene, aza-dibenzofuran, or aza-dibenzoselenophene are provided. The 3,9-linked oligocarbazole and dibenzo or aza-dibenzo moiety are separated by an aromatic spacer. The compounds may be used as non-emissive materials for phosphorescent OLEDs to provide devise having improved performance.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: January 13, 2015
    Assignee: Universal Display Corporation
    Inventor: Alexey Dyatkin
  • Publication number: 20150011509
    Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.
    Type: Application
    Filed: October 12, 2012
    Publication date: January 8, 2015
    Applicants: The Board of Trustees of the University of Illnois, The Board of Regents of the University of Texas System
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
  • Patent number: 8927121
    Abstract: Disclosed herein are compounds represented by Formula 1, wherein R1, Ar1, X, Ar2, Ar3, and Het are described herein. Compositions and light-emitting devices related thereto are also disclosed.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: January 6, 2015
    Assignee: Nitto Denko Corporation
    Inventors: Shijun Zheng, Jensen Cayas, Sheng Li, Amane Mochizuki, Hyun Sik Chae, Brett T. Harding
  • Patent number: 8927117
    Abstract: The present invention relates to a compound of the formula (1) and (2) The invention further relates to a process to produce the compound. The invention additionally relates and an electronic device containing the compound of the formula (1) or (2). The electronic device can be an organic electroluminescence devices, particularly a blue emitting device, in which compounds are used as host materials or dopants in the emitting layer and/or as hole transport materials and/or as electron transport materials.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: January 6, 2015
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Holger Heil, Philipp Stoessel
  • Patent number: 8927119
    Abstract: There is provided an organic compound having excellent characteristics, including excellent electron-injecting/transporting performance, hole blocking ability, and high stability in the thin-film state, for use as material of an organic electroluminescent device having high efficiency and high durability. There is also provided a high-efficient and high-durable organic electroluminescent device using the compound. The compound is represented by general formula (1) having a substituted anthracene ring structure and a pyridoindole ring structure. The organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, and the compound is used as a constituent material of at least one organic layer.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: January 6, 2015
    Assignee: Hodogaya Chemical Co., Ltd.
    Inventors: Norimasa Yokoyama, Shuichi Hayashi, Naoaki Kabasawa, Daizou Kanda, Shigeru Kusano
  • Publication number: 20150005339
    Abstract: The invention provides tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides solid compositions comprising tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides uses of tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist, e.g., for treating type 1 diabetes, type 2 diabetes, or obesity.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Inventors: Danilo Almariego, Dharma Rao Polisetti, Eric Benjamin, Hassan El Abdellaoui, Soumya P. Sahoo
  • Patent number: 8901305
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: December 2, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu, Tarun Kumar Maishal, Jonathan L. Ditta, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor
  • Patent number: 8895579
    Abstract: Disclosed are heterotricyclic compounds, pharmaceutical compositions, methods of treatment, and methods for selectively antagonizing a glutamate receptor. The pharmaceutical compositions may include and the methods may utilize heterotricyclic compounds that are glutamate analogues which have specificity for AMPA receptors. The pharmaceutical compositions may be utilized to treat or prevent neurological diseases or disorders.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: November 25, 2014
    Assignee: Northwestern University
    Inventors: Geoffrey T. Swanson, Martin B. Gill, Ryuichi Sakai, Masato Oikawa
  • Patent number: 8889271
    Abstract: Disclosed are a novel-structural compound including a 5-membered heterocycle, an organic electronic device using the same, and a terminal thereof.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: November 18, 2014
    Assignees: Duksan High Metal Co., Ltd., Samsung Mobile Display Co., Ltd.
    Inventors: Junghwan Park, Daesung Kim, Jungcheol Park, Kiwon Kim, Jinuk Ju, Jangyeol Baek, Soungyun Mun, Yongwook Park, Hwasoon Jung, Wonsam Kim, Jihun Byun, Sungjin Park, Eunkyung Kim, Daehyuk Choi, Dongha Kim, Hansung Yu, Kwanhee Lee, Taeshick Kim, Daeyup Shin, Mikyung Kim, Dongheon Kim
  • Patent number: 8889267
    Abstract: Embodiments of the present invention are directed to a heterocyclic compound and an organic light-emitting device including the heterocyclic compound. The heterocyclic compound is represented by Formula 1 or Formula 2. The organic light-emitting devices using the heterocyclic compounds have high-efficiency, low driving voltage, high luminance and long lifespan.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: November 18, 2014
    Assignee: Samsung Display Co., Ltd.
    Inventors: Young-Kook Kim, Seok-Hwan Hwang, Yoon-Hyun Kwak, Hye-Jin Jung, Hyung-Jun Song, Jin-O Lim, Jong-Hyuk Lee
  • Patent number: 8889706
    Abstract: The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: November 18, 2014
    Assignees: Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Jae Won Chang, Jianming Zhang, Carson C. Thoreen, Seong Woo Anthony Kang, David M. Sabatini, Qingsong Liu
  • Publication number: 20140329804
    Abstract: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Donald W. LANDRY, Shixian DENG, Ottavio ARANCIO, Jole FIORITO, Andrew WASMUTH
  • Patent number: 8871798
    Abstract: This disclosure relates to compounds of formula I: wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: October 28, 2014
    Assignee: Sanofi
    Inventors: Karl Schoenafinger, Henning Steinhagen, Bodo Scheiper, Uwe Heinelt, Volkmar Herrmann, Matthias Herrmann
  • Publication number: 20140309244
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, A, X, D1, D2 and Y3 are as defined in the claims. The invention further provides intermediates used in the preparation of these compounds, to compositions which comprise these compounds and to their use in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.
    Type: Application
    Filed: September 23, 2011
    Publication date: October 16, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Werner Zambach, Daniel Stierli, Kurt Nebel, Andrea Bortolato, Clara Massol
  • Patent number: 8859113
    Abstract: The present invention relates to novel carbazole derivatives and an organic light-emitting diode device using the same. These carbazole derivatives can simultaneously or singly be used as a hole transporting layer, a host or guest of an emitting layer or an electron transporting layer of an organic light-emitting diode device.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: October 14, 2014
    Assignee: China Petrochemical Development Corporation
    Inventors: Hsian Chan Liu, Min Sheng Chen, Chin Yi Lee
  • Patent number: 8853235
    Abstract: The present invention relates to novel crystalline polymorphic salt forms of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, processes for the preparation thereof, compositions thereof and their use in methods of treatment and prevention of conditions mediated by casein kinase (CK) and/or poly(ADP-ribose)polymerase (PARP).
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: October 7, 2014
    Assignee: Senhwa Biosciences, Inc.
    Inventors: David M. Ryckman, Michael Schwaebe
  • Patent number: 8846214
    Abstract: An amine derivative represented by the following general formula (1) and exhibiting a temperature difference of 30° C. or more as defined by the difference of [decomposition temperature (° C.) minus sublimation temperature (° C.)]: wherein R1 and R2 independently represent a substituted or unsubstituted C6-40 aryl or C5-40 heteroaryl group; and R3 and R4 independently represent a hydrogen atom, a straight-chain, branched or cyclic C1-18 alkyl or C1-18 alkoxy group, or a substituted or unsubstituted C6-40 aryl or C5-40 heteroaryl group, provided that R3 and R4 may form together a cyclic hydrocarbon group. The amine derivative is useful as an organic electroluminescent material.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: September 30, 2014
    Assignee: Tosoh Corporation
    Inventors: Shinichi Ishikawa, Naoki Matsumoto, Takanori Miyazaki, Yasushi Hara
  • Patent number: 8828561
    Abstract: A compound for an organic photoelectric device, the compound being represented by the following Chemical Formula (“CF”) 1:
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: September 9, 2014
    Assignee: Cheil Industries, Inc.
    Inventors: Hyung-Sun Kim, Eun-Sun Yu, Young-Hoon Kim, Ja-Hyun Kim, Soo-Hyun Min, Ho-Jae Lee, Eui-Su Kang, Mi-Young Chae
  • Publication number: 20140249143
    Abstract: Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 4, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Anna Lindsey Banka, Janos Botyanszki, Eric Gregory Burroughs, John George Catalano, Wendy Huang Chern, Hamilton D. Dickson, Margaret J. Gartland, Robert Hamatake, Hans Hofland, Jesse Daniel Keicher, Christopher Brooks Moore, John Bradford Shotwell, Matthew David Tallant, Jean-Philippe Therrien, Shihyun You
  • Patent number: 8815891
    Abstract: The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: August 26, 2014
    Assignee: Je Il Pharmaceutical Co., Ltd.
    Inventors: Myung-Hwa Kim, Seung-Hyun Kim, Sae-Kwang Ku, Chun-Ho Park, Bo-Young Joe, Kwang-Woo Chun, In-Hae Ye, Jong-Hee Choi, Dong-Kyu Ryu, Ji-Seon Park, Han-Chang Lee, Ji-So Choi, Young-Chul Kim
  • Publication number: 20140235855
    Abstract: Compounds of formula (I), wherein A1 represents —O—, —S— or —CH2—; A2 represents —CH2— or —O—; A3 represents C3-C8-cycloalkylene; saturated or unsaturated 4 to 8-membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen or oxygen, which group A3 is unsubstituted or substituted; A4 represents C1-C4alkylene, —C(=0)-; G represents aryl or heteroaryl, which is unsubstituted or substituted; X1 represents a nitrogen atom or CR1; R1 represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; m is 0 or 1; n is 1; the —(CH2)n— group is unsubstituted or substituted; p is 0 or 1; or pharmaceutically acceptable salts thereof are valuable for use as a medicament for the treatment of bacterial infections.
    Type: Application
    Filed: June 11, 2012
    Publication date: August 21, 2014
    Inventors: Berangere Gaucher, Franck Hubert Danel, Tong Xie, Lin Xu
  • Patent number: 8808877
    Abstract: A method of manufacturing an organic EL element, which may be a top-emitting or a transparent organic EL element, provides an organic EL element having a low driving voltage and a high efficiency. The organic EL element includes a substrate; an anode; an organic EL layer which includes at least an emissive layer, an electron transport layer and a damage-mitigating electron injection layer; and a transparent cathode composed of a transparent conductive oxide material, the damage-mitigating electron injection layer is in contact with the transparent cathode, and the damage-mitigating electron injection layer includes a crystalline oligothiophene compound.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: August 19, 2014
    Assignee: Sharp Kabushiki Kaisha
    Inventor: Yutaka Terao
  • Patent number: 8809364
    Abstract: Polycyclic aryl and polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl catalytic activity are also disclosed.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: August 19, 2014
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Dane Goff, Jiaxin Yu, Sacha Holland, Thilo J. Heckrodt, Pingyu Ding, Joane Litvak, Jing Zhang
  • Patent number: 8785001
    Abstract: The present invention relates to mixtures of organic materials, to the use of these mixtures in organic electroluminescent devices, and to organic electroluminescent devices comprising these mixtures.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: July 22, 2014
    Assignee: Merck Patent GmbH
    Inventors: Horst Vestweber, Philipp Stoessel, Holger Heil
  • Patent number: RE45216
    Abstract: An organic electroluminescent element including at least an emission layer sandwiched between an anode and a cathode, wherein the emission layer comprises at least a compound represented by Formula (A),
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: October 28, 2014
    Assignee: Konica Minolta Holdings, Inc.
    Inventors: Tatsuo Tanaka, Hideo Taka